Logo

VVOS

Vivos Therapeutics, Inc.

VVOS

Vivos Therapeutics, Inc. • NASDAQ
$2.26 ▲ 0.89% (+0.02)
Market Cap $13.31 M
52w High $7.95
52w Low $1.98
Dividend Yield 0%
P/E -1.28
Volume 108.30K
Outstanding Shares 5.89M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $6.783M ▲ $8.287M ▲ $-5.4M ▼ -79.611% ▲ $-0.49 ▲ $-5.016M ▼
Q2-2025 $3.82M ▲ $6.669M ▲ $-5.013M ▼ -131.23% ▼ $-0.55 ▼ $-4.707M ▼
Q1-2025 $3.016M ▼ $5.25M ▲ $-3.864M ▼ -128.117% ▼ $-0.45 ▲ $-3.564M ▼
Q4-2024 $3.698M ▼ $4.903M ▼ $-2.827M ▼ -76.447% ▼ $-0.48 ▼ $-2.683M ▼
Q3-2024 $3.86M $4.979M $-2.616M -67.772% $-0.4 $-2.499M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.087M ▼ $25.644M ▼ $23.112M ▲ $2.532M ▼
Q2-2025 $4.402M ▲ $26.033M ▲ $21.45M ▲ $4.583M ▲
Q1-2025 $2.342M ▼ $11.282M ▼ $6.875M ▼ $4.407M ▼
Q4-2024 $6.26M ▼ $15.284M ▼ $7.33M ▼ $7.954M ▲
Q3-2024 $6.311M $15.347M $7.682M $7.665M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.399M ▼ $-4.161M ▼ $83K ▲ $2.763M ▼ $-1.315M ▼ $-3.268M ▲
Q2-2025 $-5.013M ▼ $-3.494M ▲ $-5.906M ▼ $11.46M ▲ $2.06M ▲ $-4.265M ▼
Q1-2025 $-3.864M ▼ $-3.796M ▼ $-122K ▲ $0 ▼ $-3.918M ▼ $-3.796M ▼
Q4-2024 $-2.827M ▼ $-2.94M ▲ $-165K ▲ $3.054M ▼ $-51K ▲ $-3.105M ▲
Q3-2024 $-2.617M $-4.187M $-192K $3.787M $-592K $-3.976M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Appliances
Appliances
 $0 ▲$0 ▲$0 ▲$0 ▲
Billing Intelligence Services
Billing Intelligence Services
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲
SponsorshipSeminarOther
SponsorshipSeminarOther
 $0 ▲$0 ▲$0 ▲$0 ▲
Treatment Centers
Treatment Centers
 $0 ▲$0 ▲$0 ▲$0 ▲
VIP
VIP
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Vivos looks like a very early‑stage commercial company. Revenue is still very small and has not grown meaningfully over the last several years, which suggests that broad adoption of its products is still in the early innings. Gross profit is positive, so each sale contributes something after direct costs, but overhead—such as sales, marketing, R&D, and administration—far outweighs that contribution. The company has reported operating losses and net losses every year in the period shown, with per‑share losses amplified by share count changes and the reverse split. Overall, the income statement shows a business that has not yet scaled commercially and is still investing ahead of revenue, with persistent losses and no clear sign of profitability yet.

Balance Sheet

Balance Sheet The balance sheet is small and lean, consistent with a micro‑cap, development‑stage medical device company. Assets are modest and made up largely of cash and working capital rather than heavy equipment or facilities. Cash levels have moved up and down over time but remain limited, indicating a constrained financial cushion. There is essentially no financial debt, so the company is not burdened by interest payments, but it also relies mainly on equity to fund operations. Shareholders’ equity is modest and has shrunk in some years, reflecting continued losses and capital raises. The reverse stock split is a sign of prior share price pressure and efforts to maintain listing status, and it often goes hand‑in‑hand with past dilution.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, which means the core business is using cash rather than generating it. Free cash flow is also negative in every year shown, and capital spending needs appear very light. Because the company consumes cash and does not yet produce it from operations, it likely depends on external funding—mainly equity—to keep going. This pattern is typical for small healthcare innovators but also means that funding and cash runway are key points of risk to watch. In short, the business has not yet turned the corner to self‑funding growth and remains in a cash‑burn phase.

Competitive Edge

Competitive Edge Strategically, Vivos sits in a very attractive clinical space: sleep apnea is widespread, and existing treatments like CPAP often have compliance issues. The company’s big differentiator is its FDA‑cleared oral appliance for severe obstructive sleep apnea in adults—something no other oral appliance maker currently has. That clearance is a meaningful regulatory and marketing edge. On top of that, Vivos is building a network of trained dentists and clinicians through its VIP program. Embedding its method into practices can create switching costs and loyalty over time, which helps build a moat. At the same time, Vivos is still a tiny player in a market dominated by large, well‑funded CPAP and device companies. Its competitive strength will depend on real‑world outcomes, physician and dentist buy‑in, reimbursement access, and its ability to educate both clinicians and patients on a non‑CPAP alternative.

Innovation and R&D

Innovation and R&D Innovation is the core of the Vivos story. The Vivos Method and CARE / DNA appliances aim to remodel the airway rather than just manage symptoms, with the promise of a “treatment complete” outcome instead of lifelong device dependence. That is a powerful clinical narrative if long‑term data continue to support it. The company has also broadened its offering with home sleep testing and structured clinical protocols, trying to deliver a full ecosystem rather than just a single device. This integrated approach can deepen relationships with practitioners. Looking ahead, pediatric applications and links to conditions like ADHD are important potential growth areas, but still need broad medical community validation. New insurance billing codes expected to take effect in 2025 could be a major enabler of adoption if payers reimburse at attractive levels. Overall, Vivos is clearly innovation‑driven, but its R&D and clinical efforts must keep pace to maintain credibility and competitive distance.

Summary

Vivos Therapeutics is a small, loss‑making medical device company with an innovative, non‑invasive approach to treating sleep apnea. Financially, it remains in an early, pre‑scale stage: revenue is modest, operating and net losses are persistent, and cash flow is negative. The balance sheet is light, with little or no debt but also a limited cash buffer and history of dilution, underscored by a reverse split. Strategically, the company’s FDA clearance for severe adult OSA and its focus on a potentially “curative” airway‑remodeling approach give it a distinctive position in a large, under‑served market. Its practitioner network and expanding clinical indications (including pediatric and neurodevelopmental angles) add to the opportunity, especially if reimbursement improves with new medical codes. The key tension is clear: a compelling clinical and regulatory story set against a fragile financial profile and significant execution risk. Future outcomes will hinge on Vivos’ ability to turn its innovative method and regulatory edge into scalable adoption, payer support, and ultimately a business that can sustain itself without continual external financing.

NEWS

November 19, 2025 · 4:20 PM UTC

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Read more

November 19, 2025 · 8:30 AM UTC

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

Read more

September 30, 2025 · 8:30 AM UTC

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

Read more

September 17, 2025 · 8:30 AM UTC

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Read more